Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.

Leukemia research - 1 Oct 2020

Ciccarelli Bryan T, Hu Tinghui, Wang Qing, Kim Julia J, Whitehead Ian P

Abstract excerpt

Expression of the p210 BCR/ABL1 fusion protein has been described in virtually all patients with chronic myelogenous leukemia (CML). Previous studies have identified a guanine nucleotide exchange factor (RhoGEF) domain within BCR that is retained in p210 BCR/ABL1. Missense mutations at residues T654 (T654K) and F547 (F547L) within this domain have been reported in a CML patient in blast crisis (BC). In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Transplantation
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Eosinophilia

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mice, Inbred BALB C

Share to Rho Guanine Nucleotide Exchange Factors

Source

Identifiers

PMID: 32892149
DOI: 10.1016/j.leukres.2020.106440

Genes

BCR
ABL1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.PMID 32892149Read ↗

Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.Semantic proximity Read ↗

Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.Semantic proximity Read ↗

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.Semantic proximity Read ↗

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.Semantic proximity Read ↗

The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinaseSemantic proximity Read ↗

Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.Semantic proximity Read ↗

Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivoSemantic proximity Read ↗

BCR/ABL P210 and P190 cause distinct leukemia in transgenic miceSemantic proximity Read ↗

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaSemantic proximity Read ↗

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.Semantic proximity Read ↗

Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis of human CMLSemantic proximity Read ↗

Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.